Review Article

Long-term prognosis after cancer surgery with inhalational anesthesia and total intravenous anesthesia: a systematic review and meta-analysis

Zhaosheng Jin¹, Ru Li²*, Jiaxin Liu¹,2, Jun Lin¹

¹Department of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY 11794-8480, USA; ²Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

*Equal contributors.

Received May 27, 2019; Accepted June 21, 2019; Epub June 25, 2019; Published June 30, 2019

Abstract: Background: A number of teams have investigated the association between the mode of anesthesia and the long-term outcomes after cancer surgeries, with inconsistent conclusions. We conducted this systematic review and meta-analysis to summarize the currently available findings of clinical studies on the long-term outcomes after cancer surgery under inhalational anesthesia with volatile anesthetics (VA) and total intravenous anesthesia (TIVA) with propofol. Methods: We systematically searched PubMed, Central, EMBASE, CINAHL, Google Scholar, Web of Science citation index, US clinical trials register, UK clinical trials register, Australia and New Zealand Clinical trials register for clinical studies comparing postoperative outcomes of VA and TIVA. The included outcomes were all-cause mortality, recurrence and recurrence free survival. Meta-analysis was done using the generic inverse variance method. Results: The overall pooled hazard ratio for all-cause mortality was in favor of TIVA [Hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.60 to 0.89], so was the recurrence free survival (HR 1.22, 95% CI 1.07 to 1.41). The subgroup analysis of mortality in different cancer types did not show any remarkable difference between the intravenous or volatile anesthesia. There was also no significant difference in recurrence. Conclusion: Our meta-analysis suggests that TIVA is associated with lower all-cause mortality after cancer surgeries. As cancers of different origins can respond very differently to pharmacological intervention, more clinical trials are needed in each cancer types in order to substantiate the role of anesthesia in cancer surgery prognosis.

Keywords: Cancer, volatile anesthetics, propofol, survival, recurrence, patient outcome

Background

It is estimated that 17 million new cases of cancer were diagnosed worldwide in 2018, and 9.6 million died from cancer [1]. In the higher income countries, cancers are some of the leading causes of death [2]. Newer evidence have emerged which suggests that handling of tumor and the stress response to surgery may promote hematogenous cancer dissemination and alter the immune response to the disseminated cancer cells [3]. Perioperative factors such as anesthesia, analgesia, blood transfusion and temperature control could all interact with and impact on the surgical outcome [4-6]. Among them, one of the main modifiable factors in anesthesia is the choice of volatile anesthetics or intravenous anesthetic for the maintenance of general anesthesia. While total intravenous anesthesia (TIVA) with propofol has a slightly higher risk of intraoperative awareness and intraoperative hypotension, it also allows for faster emergence, reduced risk of postoperative nausea and vomiting [7]. In addition, more recent studies suggest that propofol may have some anti-tumor properties [8]. In contrast, volatile anesthetics (VA) such as isoflurane and sevoflurane have been reported to promote the proliferation and migration of various cancer cell lines in vitro [9-11], and increase the tumor load in vivo [12]. It therefore stands to reason that propofol TIVA may reduce cancer cell dissemination during surgery, reduce cancer recurrence and increase patient survival.

In the past few years, several studies have compared long-term outcomes of patients operated with inhalational anesthesia and TIVA and
reported varying degrees of success with TIVA. In this systematic review and meta-analysis, we compile the current evidence on the long-term cancer recurrence and survival of patients after surgery with TIVA or VA.

Methods

Search strategy

This study conformed to the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) statement [13]. We used search terms 'TIVA', 'total intravenous anesthesia', 'propofol', 'volatile anesthesia', 'cancer', 'malignancy', 'neoplasm', 'tumor', 'survival', 'recurrence', 'mortality' 'progression', 'death', 'metastasis' and their Boolean combinations in PubMed, Central, EMBASE, CINAHL, Google Scholar, Web of Science citation index, US clinical trials register, UK clinical trials register, Australia and New Zealand clinical trials register. We did not impose any language at the time of the literature search. All searches were conducted independently by two authors and discrepancies were discussed after the search process.

The inclusion criteria were: 1. Clinical studies which compared the long term (more than one year from the time of the surgery) all-cause mortality and recurrence after surgery with volatile anesthesia or propofol TIVA. We included both prospective and retrospective studies in the systematic review and meta-analysis. 2. Comparison must be reported as a risk estimate [Hazard ratio (HR) or Relative risk (RR)] with measure of precision. Alternatively, it must be possible to derive the risk estimate from the reported data. Studies which did not include data in a suitable format were excluded from the meta-analysis. Exclusion criteria was studies with regional anesthesia in one of the study arms, as regional anesthesia itself may be associated with better postoperative outcomes [5].

In addition, we also collated all the ongoing clinical trials from the searched trials registers to aid future reviews.

Data extraction

Data extraction was conducted using standardized pro-forma and checked by a second author (ZJ and RL). Extracted data included bibliographical information (author, year, PubMed ID), study design (prospective or retrospective study, number of patients in the VA and TIVA cohort, follow up length) and the outcomes (mortality, recurrence, metastasis, and whether the multivariate regression was used to eliminate potential confounding factors).

We used the Quality of Prognostic Studies (QUIPS) tool for assessing the quality of the included studies. QUIPS is a 6-item questionnaire designed for assessing prognostic studies; it could be applied to both prospective and retrospective studies. Each item represents a risk category, and can be determined to be low, medium or high risk [14]. All assessments were done by two authors independently but at the same time, any disagreement was discussed with and resolved by a third author (JL).

Statistical analysis

Meta-analysis was conducted for any outcomes reported in more than one study. Otherwise it is reported descriptively. Review Manager (RevMan) Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for the pooled analysis. For each outcome, the pooled hazard ratio (HR) of TIVA against VA was computed from the hazard ratios of the individual studies using generic inverse variance method with 95% confidence interval (CI) [15]. In studies which did not conduct formal survival studies and report the hazard ratio, relative risk value was used as the estimate for hazard ratio using methods described by Tiemey et al [16]. Heterogeneity was assessed using Cochrane’s I² statistic, expressed as a percentage term; higher percentage suggests higher degree of heterogeneity [17].

Due to the inherent heterogeneity in the cancer types and stages, we used the random effect model for all outcomes. In addition, subgroup analyses were conducted for organ involved and for prospective against retrospective studies. Due to the small number of studies for each organ system and the inherent heterogeneity in cancer stages, we used random effect models in all subgroup analyses. Publication bias was assessed using Egger’s regression (statistical significance indicates high probability of publication bias) using statistical package.
Anesthesia and cancer surgery prognosis: a meta-analysis

Figure 1. Flow chart of the literature search. *: one study included subgroups of breast and colorectal cancer.

Results

Description of included studies

The last literature search was done on May 20th, 2019. Our literature search process identified a total of 1257 studies, of which 32 passed the title and abstract screening. There were 17 duplicates which were removed. Of the remaining studies, three were removed on further reading, two used epidural anesthesia, which is independently associated with better postoperative outcomes; one was a study protocol (see Figure 1).

Twelve studies were included in the meta-analysis, and their characteristics was summarized in Table 1 [20-31]. There were two prospective studies, with sample size between 28 and 80 participants, and ten retrospective studies, with sample size between 294 and 7030 case records. In terms of cancer type, there were five studies on breast cancer surgery and two studies on colorectal cancer surgery. In addition, there was one study each for esophageal, bladder, gastric, glioma, and lung cancer surgery outcomes. The study by Enlund et al included cases of both breast and colorectal surgery and reported the outcomes separately [21]. The study by Wigmore included 7030 case records of patients who had any elective cancer surgery [27]. The median follow-up of the studies ranges from 1 year to over 5 years.

The risk of bias assessment for each study is displayed in Figure 2. The main sources of potential bias we encountered during the assessment were with the study participant attrition, either due to authors not reporting the number of cases lost to follow up [22-25, 32] or due to considerably uneven incidence of censoring in the cohorts [21]. Another source of bias was study confounding, mainly due to authors not reporting the tumor stage and comorbidities [21, 23, 27].

We also identified seven ongoing clinical trials, their characteristics as well as estimated completion times are listed in Table 2.

All-cause mortality

All twelve studies reported risk estimates for all-cause mortality. Both of the prospective studies reported the raw mortality rate at the end of the study. Nine of the ten retrospective studies conducted formal survival analysis and reported mortality HR based on multivariate regression, but the study by Lee et al [24] only reported the raw mortality rate at the end of the follow-up period.

The pooled HR for mortality demonstrated significant difference in favor of the TIVA cohort, there was however considerable heterogeneity (HR = 0.73, 95% CI 0.60 to 0.89, \(I^2 = 79\%\), Egger's regression \(P = 0.78\)) (Figure 3). Due to the significant heterogeneity amongst the stud-
Table 1. Characteristics of included trials

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Methods</th>
<th>Participants</th>
<th>Interventions</th>
<th>Outcomes</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sofra 2013 [26]</td>
<td>RCT, unclear blinding</td>
<td>28 Bladder cancer patients operated between 2010-2011</td>
<td>Propofol vs sevoflurane</td>
<td>Survival</td>
<td></td>
</tr>
<tr>
<td>Wigmore 2016 [27]</td>
<td>Single centre retrospective analysis of hospital records</td>
<td>7030 Patients for all cancer surgery between 2010-2013</td>
<td>Propofol vs volatiles</td>
<td>Survival</td>
<td>Propensity matched</td>
</tr>
<tr>
<td>Yan 2018 [29]</td>
<td>RCT, blinding not clear</td>
<td>80 Breast cancer patients operated in 2016</td>
<td>Propofol vs sevoflurane</td>
<td>Survival, recurrence, recurrence free survival</td>
<td></td>
</tr>
<tr>
<td>Yoo 2018 [31]</td>
<td>Single centre retrospective analysis of hospital records</td>
<td>5331 Breast cancer patients operated between 2005-2013</td>
<td>Propofol vs volatiles</td>
<td>Survival and recurrence free survival</td>
<td>Propensity matched</td>
</tr>
</tbody>
</table>
ies, we conducted a subgroup analysis for the different organ involvement. This did not demonstrate any significant difference between TIVA and VA (Breast cancer: HR = 1.14, 95% CI 0.92 to 1.40, Colorectal cancer: HR = 0.57, 95% CI 0.23 to 1.41) (Figure 4).

We then conducted a subgroup analysis comparing the retrospective studies which conducted formal survival analysis, and studies which only reported raw mortality data. The subgroup analysis found significant HR in favor of TIVA in the survival analysis studies, but not in the raw mortality data studies (survival analysis data: HR = 0.73, 95% CI 0.59 to 0.90, I² = 84%; raw mortality data: HR = 0.80, 95% CI 0.40 to 1.60, I² = 0%). There were more studies in the survival analysis subgroup, and the studies in the survival analysis subgroup had comparatively smaller confidence interval, which may have contributed to the difference (Figure 5).

**Recurrence and recurrence-free survival**

There were five studies which reported risk estimates for recurrence. Three studies were on breast cancer and one study each on lung and colon cancer. The pooled HR slightly favors TIVA, but it was not statistically significant (HR = 0.73, 95% CI 0.47 to 1.14, I² = 61%, Figure 6). Subgroup analysis of the three breast cancer studies however was significantly in favor of TIVA (HR = 0.56, 95% CI 0.35 to 0.88, I² = 0%, Egger’s regression P = 0.48, Figure 6). Three studies reported risk estimates for recurrence-free survival, two for breast cancer and one for esophagus cancer. The pooled HR significantly favors TIVA (HR = 1.22, 95% CI 1.07 to 1.40, I² = 0%, Egger’s regression P = 0.81, Figure 7).

**Discussion**

Our meta-analysis suggests that in the clinical context, the choice of anesthetic agent for cancer surgery may affect long-term postoperative outcomes. TIVA appears to be associated with lower all-cause mortality and better recurrence-free survival than volatile anesthetics. This is consistent with the pre-clinical findings discussed above. It is important to consider that tumors may have various responses to the anesthetics. Indeed, the breast cancer subgroup analysis revealed lower recurrence rate but no difference in overall mortality with TIVA, different to the pooled study data. However, our attempt to conduct subgroup analysis was limited by the available number of viable subgroups (breast cancer and colorectal cancer) and number of studies (2 to 5 studies) in each sub-group. More studies are needed for each organ systems to have a sufficiently powered meta-analysis.

In order to assess the effect of study design on the heterogeneity of the results, we conducted subgroup analysis according to study design, the survival analysis studies (all retrospective studies) had a smaller confidence interval compared to the raw mortality rate studies (2 RCTs and 1 retrospective study), but the hazard ratio studies were similar. It is therefore unlikely that the study design is source of heterogeneity in the pooled analysis.
### Table 2. List of ongoing clinical trials comparing TIVA to volatile aneasthesia

<table>
<thead>
<tr>
<th>Trial identifier</th>
<th>Cancer type</th>
<th>Estimated enrollment</th>
<th>Study arms</th>
<th>Outcomes</th>
<th>Trial status and estimated completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03193710</td>
<td>Colorectal cancer</td>
<td>260</td>
<td>Propofol vs Sevoflurane</td>
<td>Cancer free survival, Recurrence, metastasis up to 5 years</td>
<td>Recruiting, October 2023</td>
</tr>
<tr>
<td>NCT03034096</td>
<td>All cancer surgery</td>
<td>2000</td>
<td>Propofol vs volatiles</td>
<td>Mortality, recurrence free survival at least 2 years</td>
<td>Recruiting, December 2020</td>
</tr>
<tr>
<td>NCT02839668</td>
<td>Breast cancer</td>
<td>120</td>
<td>Propofol vs sevoflurane; +/- Lidocaine</td>
<td>Survival up to 1 year</td>
<td>Ongoing, December 2018</td>
</tr>
<tr>
<td>NCT02786329</td>
<td>Colorectal cancer</td>
<td>450</td>
<td>Propofol vs sevoflurane</td>
<td>Recurrence up to 5 years</td>
<td>Recruiting, December 2021</td>
</tr>
<tr>
<td>NCT02756312</td>
<td>Malignant Gioma</td>
<td>500</td>
<td>Propofol vs volatiles</td>
<td>Progression free survival up to 1 year</td>
<td>Ongoing, December 2018</td>
</tr>
<tr>
<td>NCT01975064</td>
<td>Breast, colorectal cancer</td>
<td>8000</td>
<td>Propofol vs sevoflurane</td>
<td>Survival after 5 years</td>
<td>Recruiting, December 2022</td>
</tr>
<tr>
<td>NCT02660411</td>
<td>All cancer surgery</td>
<td>1200</td>
<td>Propofol vs sevoflurane</td>
<td>Survival and recurrence free survival up to 3 years</td>
<td>Ongoing, December 2020</td>
</tr>
</tbody>
</table>
In contrast to overall mortality, the meta-analysis of cancer recurrence data did not demonstrate significant difference between TIVA and VA. This may be due to the following reasons. First, this could be due to the small number of studies and lack of statistical power. More studies are needed for each tumor types in order to accurately interpret the effect of mode of anesthesia. Second, there have been concerns that choice of anesthetic agent may have...
a direct impact on postoperative mortality, unrelated to its effect on cancer cells [33, 34]. However, Uhlig et al conducted a meta-analysis of TIVA vs. VA in all surgery type and found no significant difference in mortality up to one year postoperatively [35]. Therefore, we suggest that the limited number of available studies reporting recurrence would still be the major reason for the differential observations between overall mortality and recurrence.
Anesthesia and cancer surgery prognosis: a meta-analysis

Some laboratory studies support that propofol is favorable to volatile anesthetics but remains controversial. Direct effects of anesthetics on various cancer cells have been explored for both volatile anesthetics and intravenous propofol, reviewed in [8, 36, 37]. Most studies focused on the changes of cancer cell phenotypes, including proliferation, migration, and invasion. Among reported molecular targets, Hypoxia-inducible factor 1-alpha (HIF-1α) is the most extensively studied one in laboratory. Isoflurane was shown to switch on HIF-1α signaling pathway in prostate cancer, lung cancer and renal cancer cells [10, 38, 39]. Sevoflurane was found to activate HIF-1α and downstream phosphorylated protein kinase B (p-Akt) in glioma stem cells [40]. In the opposite, propofol has been suggested to suppress the activation of HIF-1α induced by sevoflurane in prostate cancer cells [38]. To fully decipher the effect of anesthetics on cancer cells, carefully designed systematic analysis, as exampled in a study published by Huitink et al [41], are required to take into consideration of cancer heterogeneity and proper approaches to convert the identified targets into clinical application.

Another important aspect of anesthetics may affect the cancer patient outcome could be the impact on immunity. Volatile anesthetics have been shown to systemically impair immune function by inducing T-lymphocyte apoptosis, attenuating nature killer (NK) cell activity, decrease Th1/Th2 ratio, and increase levels of pro-tumorigenic cytokines and matrix metalloproteinase (MMPs) [42-44]. In contrast, propofol increased cytotoxic T-lymphocyte activity, preserved NK cell function, and decreased pro-tumorigenic cytokines [43-45]. Propofol also exhibited anti-inflammatory and anti-oxidation properties through inhibiting cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) function [46]. Preclinical studies as-to-now suggested that the volatile anesthetic-induced immuno-suppression may be involved in cancer recurrence and metastasis, whereas propofol-based anesthesia has the opposite effect. The causal link between anesthetics, perioperative immuno-suppression, and survival remains to be elucidated.

Regardless of the exact mechanism, the choice of TIVA or VA is a potentially modifiable factor in cancer management, the findings from our meta-analysis indicate that TIVA was associated with lower postoperative mortality. We need further prospective clinical trials to explicate the role of anesthetic agent on cancer prognosis. There are several ongoing clinical trials in this area which may shed some light on the topic (Table 2). However, the larger clinical trials involving common cancer types are not due to be completed for several years. We therefore believe summary of the current literature is necessary in the meantime in order to aid decision making.

Incidentally, Yap et al conducted a similar review concurrent to our meta-analysis and reported that overall survival and recurrence-free survival was significantly better with TIVA [47], which is consistent with the findings of
our meta-analysis. However, our meta-analysis also included cancer recurrence as an additional outcome and found that the choice of anesthetic agent did not affect the risk of recurrence. In summary, more studies are needed in order to generate a more definitive conclusion.

Limitations

During the risk of bias assessments, we noticed that the most prominent sources of risk of bias were participant attrition and control of confounding factors. Most of the included studies either did not report their loss of participants during the follow-up periods or reported significantly more participant loss in one cohort than the other. In addition, five of twelve studies did not adequately take into account confounding factors such as patient co-morbidities or tumor grading. Those are issues for consideration for any groups looking to do further studies on the topic.

In addition to the risk assessment of the studies, this meta-analysis has a few important limitations. Firstly, this meta-analysis only covers limited types of cancer and there were only sufficient studies to conduct subgroup analysis on two cancer types. Given the diverse phenotype of cancerous cells, the results here should be interpreted with caution in clinical practice. Secondly, the included papers are mostly retrospective studies; this increases the risk of errors, for example bias in allocation to TIVA vs VA, or in selection of included cases, as well as potentially confounding factors. However, it is worth noting that seven of the ten retrospective studies included a propensity matched cohort, which does limit the risk of confounders to an extent. Lastly, while our meta-analysis has established a possible association, it does not infer causality or explains the underlying mechanism. We believe that more pre-clinical studies are needed in order to better understand the molecular mechanisms underlying the effect of anesthetic agents in cancer.

Conclusion

We conducted a meta-analysis of 12 studies, including more than 21,000 patients, which demonstrated that TIVA is associated with slightly lower mortality after cancer surgery, while its effect on recurrence and recurrence free survival remained inconclusive. More prospective clinical trials are needed to expand on the evidence base on anesthetic practice for cancer surgery.

Acknowledgements

We thank Yaohua He, MD, PhD (Senior Director, Head of Biostatistics, Taiho Oncology, Inc., Princeton, NJ, 08540) for statistic assistance. Our laboratory is funded by the Department of Anesthesiology at Stony Brook University.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jun Lin, Department of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY 11794-8480, USA. Tel: 631 444 2975; E-mail: jun.lin@stonybrookmedicine.edu

References

[9] Iwasaki M, Zhao H, Jaffer T, Unwith S, Benzonana L, Lian Q, Sakamoto A and Ma D. Volatile anaesthetics enhance the metastasis
Anesthesia and cancer surgery prognosis: a meta-analysis


